Demographics and clinical characteristics
| . | Doublet TAG-AZA Cohort A (n = 19) . | Triplet TAG-AZA-VEN Cohort B, all patients (1L and R/R AML) (n = 37) . | Triplet TAG-AZA-VEN Cohort B, 1L AML only (n = 26) . |
|---|---|---|---|
| Age (median, range) | 62 (40-77) | 70 (39-81) | 71 (60-81) |
| Diagnosis | |||
| 1L AML | 5 | 26 | 26 |
| R/R AML | 9 | 11 | |
| MDS | 5 | ||
| n (%) | n (%) | n (%) | |
| Gender | |||
| Female | 7 (36.8) | 15 (40.5) | 10 (38.5) |
| Male | 12 (63.2) | 22 (59.5) | 16 (61.5) |
| Race | |||
| White | 13 (68.4) | 32 (86.5) | 24 (92.3) |
| Other | 4 (21.1) | 3 (8.1) | 2 (7.7) |
| Asian | 1 (5.3) | 2 (5.4) | 0 (0) |
| More than 1 | 1 (5.3) | 0 (0) | 0 (0) |
| Ethnicity | |||
| Non-Hispanic | 14 (73.7) | 33 (89.2) | 24 (92.3) |
| Hispanic or Latino | 3 (15.8) | 3 (8.1) | 2 (7.7) |
| Not known | 2 (10.5) | 1 (2.7) | 0 (0) |
| ECOG PS | |||
| 2 | 3 (15.8) | 7 (18.9) | 2 (7.7) |
| 1 | 11 (57.9) | 24 (64.9) | 19 (73.1) |
| 0 | 5 (26.3) | 6 (16.2) | 5 (19.2) |
| Additional characteristics of the triplet TAG-AZA-VEN cohort B, 1L AML (n=26) | |||
| n (%) | |||
| ELN 2022 adverse risk | 26 (100) | ||
| Any TP53 mutation | 13 (50) | ||
| Multi-hit TP53 | 9/13 | ||
| One TP53 mutation with 17p deletion | 7/13 | ||
| Two TP53 mutations | 2/13 | ||
| Complex karyotype | 8 (30.7) | ||
| Secondary AML | 8 (30.7) | ||
| Therapy-related AML | 5 (19.2) | ||
| pDC-AML | 2 (7.7) | ||
| Baseline bone marrow blasts (median, range) | 58% (20-91) | ||
| Known extramedullary disease at screening | 0 | ||
| . | Doublet TAG-AZA Cohort A (n = 19) . | Triplet TAG-AZA-VEN Cohort B, all patients (1L and R/R AML) (n = 37) . | Triplet TAG-AZA-VEN Cohort B, 1L AML only (n = 26) . |
|---|---|---|---|
| Age (median, range) | 62 (40-77) | 70 (39-81) | 71 (60-81) |
| Diagnosis | |||
| 1L AML | 5 | 26 | 26 |
| R/R AML | 9 | 11 | |
| MDS | 5 | ||
| n (%) | n (%) | n (%) | |
| Gender | |||
| Female | 7 (36.8) | 15 (40.5) | 10 (38.5) |
| Male | 12 (63.2) | 22 (59.5) | 16 (61.5) |
| Race | |||
| White | 13 (68.4) | 32 (86.5) | 24 (92.3) |
| Other | 4 (21.1) | 3 (8.1) | 2 (7.7) |
| Asian | 1 (5.3) | 2 (5.4) | 0 (0) |
| More than 1 | 1 (5.3) | 0 (0) | 0 (0) |
| Ethnicity | |||
| Non-Hispanic | 14 (73.7) | 33 (89.2) | 24 (92.3) |
| Hispanic or Latino | 3 (15.8) | 3 (8.1) | 2 (7.7) |
| Not known | 2 (10.5) | 1 (2.7) | 0 (0) |
| ECOG PS | |||
| 2 | 3 (15.8) | 7 (18.9) | 2 (7.7) |
| 1 | 11 (57.9) | 24 (64.9) | 19 (73.1) |
| 0 | 5 (26.3) | 6 (16.2) | 5 (19.2) |
| Additional characteristics of the triplet TAG-AZA-VEN cohort B, 1L AML (n=26) | |||
| n (%) | |||
| ELN 2022 adverse risk | 26 (100) | ||
| Any TP53 mutation | 13 (50) | ||
| Multi-hit TP53 | 9/13 | ||
| One TP53 mutation with 17p deletion | 7/13 | ||
| Two TP53 mutations | 2/13 | ||
| Complex karyotype | 8 (30.7) | ||
| Secondary AML | 8 (30.7) | ||
| Therapy-related AML | 5 (19.2) | ||
| pDC-AML | 2 (7.7) | ||
| Baseline bone marrow blasts (median, range) | 58% (20-91) | ||
| Known extramedullary disease at screening | 0 | ||
1L AML, previously untreated AML; ECOG PS, Eastern Cooperative Oncology Group Performance Status; pDC, plasmacytoid dendritic cell.